Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Building A Blockbuster

A deep dive into the dynamics of blockbuster drugs.

READ NOW

Featured Stories


Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal

Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab. 

Deals M & A Immune Disorders

More Cost Cuts At Pfizer Bring Total Savings To $5.5bn

A new round of cost-cutting at Pfizer will deliver savings of $1.5bn by the end of 2027, the company reported in an SEC filing.

Companies Business Strategies Sales & Earnings

SixPeaks Debuts With Obesity Candidates And AstraZeneca Seal Of Approval

The start-up plans to enter the clinic next year with a muscle-sparing activin receptor IIA/B antibody, while AstraZeneca has an exclusive option to acquire the company.

Deals Financing Metabolic Disorders

Asia Spotlight

Lupin CEO Highlights Structural Support For Generics Pricing, Sees gMyrbetriq Relaunch

Lupin’s CEO spoke of US drug shortages having led to recognition of the need for structural and regulatory support for viable pricing of generic drugs. She was also optimistic on the relaunch of a Myrbetriq generic after Astellas obtained a temporary restraining order against Lupin and Zydus just a few days post an at-risk launch by the latter two companies

Commercial Sales & Earnings

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Mythic Therapeutics Faces An Acid Test

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

Emerging Company Profile Biologics

Finance Watch: AltruBio, Pheon Raise Venture Capital Mega-Rounds

Private Company Edition: AltruBio raised up to $225m and Pheon garnered $120m in series B financings, while Lycia brought in $106.6m in series C cash. Also, Sands Capital closed its third life science fund, totaling $555m, and NewVale Capital debuted with $167m for life science services.

Financing Innovation

Stock Watch: Paradoxical Q1 Earnings Reactions

Falling sales are not typically welcomed by investors, while good revenue growth is prized. The first-quarter earnings season provided exceptions to this rule, and then there was Amgen.

Stock Watch Commercial

Pipeline Watch: Six Approvals And 12 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
Interviews

Mythic Therapeutics Faces An Acid Test

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

Emerging Company Profile Biologics

AstraZeneca Confident Of Cementing Lead In Respiratory

The UK major’s head of respiratory and immunology, Pablo Panella, tells Scrip that AstraZeneca’s well established presence in the field “gives us an edge.”

Respiratory Clinical Trials

NGGT Progresses First US Gene Therapy Trials For Rare Conditions

Next Generation Gene Therapeutics is fast-tracking clinical trials in the US for its gene therapy candidates for Bietti's crystalline dystrophy and classic phenylketonuria, supported by China data, the Chinese venture's CEO tells Scrip in an interview.

China Clinical Trials

Ajax Set To ‘Attack JAK’ In Myelofibrosis With $95m In Series C Cash

Ajax Therapeutics plans to take its type II JAK2 inhibitor into the clinic during the second half of 2024 with the aim of modifying disease in a way that first-generation type I inhibitors do not. 

Financing Growth
See All
Graphics

Development Versus Dealmaking: How To Obtain A Blockbuster

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

Companies Deals

Rapid Rise Or Slow Roll: How Long Does It Take To Become A Blockbuster?

Scrip analyzed data on top-selling drugs to see how long it takes to surpass $1bn in revenues and grow into $5bn and even $10bn brands.

Launches Commercial

Blockbusters By Indication: More Begets More

A Scrip analysis of the industry’s top-selling drugs examines the power of indication expansion to drive revenue growth.

Launches Business Strategies

The Life Of A Blockbuster

The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs to see which are forecast to make the most at peak and over a 14-year time horizon.

Launches Business Strategies
See All
Recent Stories

Tremfya Shows Head-To-Head Edge Versus Stelara In Crohn’s

Johnson & Johnson tested Tremfya against its established Stelara as the “benchmark” in IBD. Tremfya, already up for approval in ulcerative colitis, is planned for filing in Crohn’s later in 2024.

Clinical Trials Business Strategies

Rezolute Sees Big Opportunity For Oral Eye Disease Drug

The company reported positive topline data from a Phase II study testing RZ402 in patients with diabetic macular edema.

Clinical Trials Ophthalmic

Why Pheon Is Keeping Mum Over Target For Novel ADC

Intense competition in ADCs means Pheon is holding back details on its technology as it heads into Phase I studies after a $120m series B fundraising.

Companies Oncology

Mythic Therapeutics Faces An Acid Test

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

Emerging Company Profile Biologics

AstraZeneca Targets $80bn Sales By 2030 But Analysts Still To Be Convinced

The UK company has unveiled a new strategy for 2030 and beyond but analysts' forecasts fall around $15bn short of the company’s own projections.

Commercial Clinical Trials

BeiGene-Glenmark Deal Set Tevimbra, Brukinsa On India Trajectory

Glenmark to progress BeiGene’s key assets in India, a market where rival PD-1 inhibitors and BTK inhibitors have a head start. All eyes are on the regulatory pathway, which provides for a waiver of local trial requirements for new drugs on a case-by-case basis, subject to certain criteria.

Commercial India

Finance Watch: AltruBio, Pheon Raise Venture Capital Mega-Rounds

Private Company Edition: AltruBio raised up to $225m and Pheon garnered $120m in series B financings, while Lycia brought in $106.6m in series C cash. Also, Sands Capital closed its third life science fund, totaling $555m, and NewVale Capital debuted with $167m for life science services.

Financing Innovation

Lilly Inks Follow-Up Radiopharmaceuticals Deal With Aktis

The big pharma will pay $60m upfront and make an equity investment in the Boston-based startup.

Deals Cancer

Sanofi Cements Artificial Intelligence Ambitions With OpenAI and Formation Pact

The French drugmaker’s aim is to become the first pharma company powered by artificial intelligence at scale, and the collaborations keep coming.

Artificial Intelligence Deals

GSK Tailors SWIFT Readout Towards Asthma Approval

The twice-yearly depemokimab will soon head to the regulators, but it will need to succeed repeatedly if it is to make the £3bn peak sales GSK is hoping for.

Clinical Trials Respiratory

'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o

Faster, more powerful and able to handle voices and visual images, newly released AI platform GPT-4o could potentially accelerate many tasks currently handled by pharma firms' medical affairs professionals, who are exploring ways to keep themselves relevant while embracing the unprecedented technology, DIA China hears.

Artificial Intelligence China

Amgen/AstraZeneca’s Tezspire Shows Efficacy In Broader COPD Population

Anti-TSLP antibody Tezspire (tezepelumab) showed efficacy in a Phase IIa study versus placebo in COPD patients with lower eosinophil levels than those tested in Dupixent’s pivotal studies.

Clinical Trials Respiratory
UsernamePublicRestriction

Register